These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 8533995

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG, Macdonald JK.
    Cochrane Database Syst Rev; 2012 Oct 17; 10():CD000544. PubMed ID: 23076890
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG, Macdonald JK.
    Cochrane Database Syst Rev; 2012 Oct 17; 10():CD000543. PubMed ID: 23076889
    [Abstract] [Full Text] [Related]

  • 5. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.
    Sninsky CA, Cort DH, Shanahan F, Powers BJ, Sessions JT, Pruitt RE, Jacobs WH, Lo SK, Targan SR, Cerda JJ.
    Ann Intern Med; 1991 Sep 01; 115(5):350-5. PubMed ID: 1863024
    [Abstract] [Full Text] [Related]

  • 6. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK.
    Cochrane Database Syst Rev; 2016 Apr 21; 4(4):CD000543. PubMed ID: 27101467
    [Abstract] [Full Text] [Related]

  • 7. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F.
    Am J Gastroenterol; 2005 Nov 21; 100(11):2478-85. PubMed ID: 16279903
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.
    Miner P, Hanauer S, Robinson M, Schwartz J, Arora S.
    Dig Dis Sci; 1995 Feb 21; 40(2):296-304. PubMed ID: 7851193
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D.
    BMJ; 1989 Jan 14; 298(6666):82-6. PubMed ID: 2563951
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y.
    Clin Gastroenterol Hepatol; 2006 Dec 14; 4(12):1502-6. PubMed ID: 17101300
    [Abstract] [Full Text] [Related]

  • 17. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M.
    Am J Gastroenterol; 1993 Aug 14; 88(8):1188-97. PubMed ID: 8338086
    [Abstract] [Full Text] [Related]

  • 18. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Sutherland L, Macdonald JK.
    Cochrane Database Syst Rev; 2006 Apr 19; (2):CD000544. PubMed ID: 16625537
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.